Fasting Versus Nonfasting and Low-Density Lipoprotein Cholesterol Accuracy
- PMID: 29038168
- DOI: 10.1161/CIRCULATIONAHA.117.030677
Fasting Versus Nonfasting and Low-Density Lipoprotein Cholesterol Accuracy
Abstract
Background: Recent recommendations favoring nonfasting lipid assessment may affect low-density lipoprotein cholesterol (LDL-C) estimation. The novel method of LDL-C estimation (LDL-CN) uses a flexible approach to derive patient-specific ratios of triglycerides to very low-density lipoprotein cholesterol. This adaptability may confer an accuracy advantage in nonfasting patients over the fixed approach of the classic Friedewald method (LDL-CF).
Methods: We used a US cross-sectional sample of 1 545 634 patients (959 153 fasting ≥10-12 hours; 586 481 nonfasting) from the second harvest of the Very Large Database of Lipids study to assess for the first time the impact of fasting status on novel LDL-C accuracy. Rapid ultracentrifugation was used to directly measure LDL-C content (LDL-CD). Accuracy was defined as the percentage of LDL-CD falling within an estimated LDL-C (LDL-CN or LDL-CF) category by clinical cut points. For low estimated LDL-C (<70 mg/dL), we evaluated accuracy by triglyceride levels. The magnitude of absolute and percent differences between LDL-CD and estimated LDL-C (LDL-CN or LDL-CF) was stratified by LDL-C and triglyceride categories.
Results: In both fasting and nonfasting samples, accuracy was higher with the novel method across all clinical LDL-C categories (range, 87%-94%) compared with the Friedewald estimation (range, 71%-93%; P≤0.001). With LDL-C <70 mg/dL, nonfasting LDL-CN accuracy (92%) was superior to LDL-CF accuracy (71%; P<0.001). In this LDL-C range, 19% of fasting and 30% of nonfasting patients had differences ≥10 mg/dL between LDL-CF and LDL-CD, whereas only 2% and 3% of patients, respectively, had similar differences with novel estimation. Accuracy of LDL-C <70 mg/dL further decreased as triglycerides increased, particularly for Friedewald estimation (range, 37%-96%) versus the novel method (range, 82%-94%). With triglycerides of 200 to 399 mg/dL in nonfasting patients, LDL-CN <70 mg/dL accuracy (82%) was superior to LDL-CF (37%; P<0.001). In this triglyceride range, 73% of fasting and 81% of nonfasting patients had ≥10 mg/dL differences between LDL-CF and LDL-CD compared with 25% and 20% of patients, respectively, with LDL-CN.
Conclusions: Novel adaptable LDL-C estimation performs better in nonfasting samples than the fixed Friedewald estimation, with a particular accuracy advantage in settings of low LDL-C and high triglycerides. In addition to stimulating further study, these results may have immediate relevance for guideline committees, laboratory leadership, clinicians, and patients.
Clinical trial registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01698489.
Keywords: cholesterol, LDL; data accuracy; fasting.
© 2017 American Heart Association, Inc.
Comment in
-
The Future of Low-Density Lipoprotein Cholesterol in an Era of Nonfasting Lipid Testing and Potent Low-Density Lipoprotein Lowering.Circulation. 2018 Jan 2;137(1):20-23. doi: 10.1161/CIRCULATIONAHA.117.031857. Circulation. 2018. PMID: 29279336 Free PMC article. No abstract available.
Similar articles
-
Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile.JAMA. 2013 Nov 20;310(19):2061-8. doi: 10.1001/jama.2013.280532. JAMA. 2013. PMID: 24240933 Free PMC article.
-
Impact of improved low-density lipoprotein cholesterol assessment on guideline classification in the modern treatment era-Results from a racially diverse Brazilian cross-sectional study.J Clin Lipidol. 2019 Sep-Oct;13(5):804-811.e2. doi: 10.1016/j.jacl.2019.07.002. Epub 2019 Jul 9. J Clin Lipidol. 2019. PMID: 31383603
-
Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines.Circulation. 2018 Jul 17;138(3):244-254. doi: 10.1161/CIRCULATIONAHA.117.032463. Epub 2018 Mar 5. Circulation. 2018. PMID: 29506984 Clinical Trial.
-
Accuracy of 23 Equations for Estimating LDL Cholesterol in a Clinical Laboratory Database of 5,051,467 Patients.Glob Heart. 2023 Jun 19;18(1):36. doi: 10.5334/gh.1214. eCollection 2023. Glob Heart. 2023. PMID: 37361322 Free PMC article.
-
Nonfasting versus fasting lipid profile for cardiovascular risk prediction.Pathology. 2019 Feb;51(2):131-141. doi: 10.1016/j.pathol.2018.09.062. Epub 2018 Dec 3. Pathology. 2019. PMID: 30522787 Review.
Cited by
-
World Heart Federation Cholesterol Roadmap 2022.Glob Heart. 2022 Oct 14;17(1):75. doi: 10.5334/gh.1154. eCollection 2022. Glob Heart. 2022. PMID: 36382159 Free PMC article. Review.
-
Statin Treatment in Specific Patient Groups: Role for Improved Cardiovascular Risk Markers.J Clin Med. 2020 Nov 21;9(11):3748. doi: 10.3390/jcm9113748. J Clin Med. 2020. PMID: 33233352 Free PMC article. Review.
-
Remnant cholesterol, lipid ratios, and the severity of coronary artery lesions: a retrospective cohort study in patients with coronary heart disease.Front Cardiovasc Med. 2025 Mar 10;12:1516326. doi: 10.3389/fcvm.2025.1516326. eCollection 2025. Front Cardiovasc Med. 2025. PMID: 40129766 Free PMC article.
-
The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Nonfasting Remnant Cholesterol in a Real World Population.J Lipids. 2018 Jul 19;2018:9194736. doi: 10.1155/2018/9194736. eCollection 2018. J Lipids. 2018. PMID: 30105099 Free PMC article.
-
Advanced Molecular Imaging (MRI/MRS/1H NMR) for Metabolic Information in Young Adults with Health Risk Obesity.Life (Basel). 2021 Oct 1;11(10):1035. doi: 10.3390/life11101035. Life (Basel). 2021. PMID: 34685406 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical